Literature DB >> 24933452

Concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: treatment outcomes of a prospective, multicentric clinical study.

Fang Wu1, Rensheng Wang2, Heming Lu3, Bo Wei4, Guosheng Feng3, Guisheng Li5, Meilian Liu6, Haolin Yan7, Jinxian Zhu8, Yong Zhang1, Kai Hu1.   

Abstract

BACKGROUND AND
PURPOSE: To evaluate long-term outcome in locoregionally advanced nasopharyngeal carcinoma (NPC) treated with intensity-modulated radiation therapy (IMRT) and concurrent chemotherapy.
MATERIAL AND METHODS: Between January 2006 and August 2008, 249 patients with stage III-IVb NPC were treated by IMRT plus concurrent chemotherapy in this multicenter prospective study.
RESULTS: With a mean follow-up of 54.1 months, the 5-year actuarial rates of overall survival (OS), local recurrence-free survival (LRFS), regional recurrence-free survival (RRFS), and distant metastasis-free survival (DMFS) were 78.4%, 86.8%, 88.4%, 78.0%, respectively. There were 29 local recurrences, 25 regional recurrences and 52 distant metastases, respectively. Distant metastasis is the main cause of treatment failure. N-stage was an independent prognostic factor for LRFS, RRFS, DMFS and OS. Acute toxicity ⩾grade III mainly consisted of mucositis (34.9%), neutropenia (11.2%), xerostomia (5.6%), and dermatitis (5.2%). The main documented late toxicity was xerostomia, and the severity of xerostomia decreased over time. At 24 months after treatment, 13.2% of patients had grade 2 xerostomia, and none had grade 3 or 4 xerostomia.
CONCLUSIONS: IMRT with concurrent cisplatin chemotherapy resulted in encouraging rates of local and distant control and overall survival with acceptable rates of acute and limited rates of late toxicity in patients with locoregionally advanced NPC. Distant metastasis remained the main cause of failure. More effective systemic therapy should be explored for patients with advanced N-stage.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Clinical outcome; Concurrent chemoradiotherapy; Intensity-modulated radiotherapy; Nasopharyngeal carcinoma; Prospective study

Mesh:

Substances:

Year:  2014        PMID: 24933452     DOI: 10.1016/j.radonc.2014.05.005

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  50 in total

1.  Non-endemic locoregionally advanced nasopharyngeal carcinoma: long-term outcome after induction plus concurrent chemoradiotherapy in everyday clinical practice.

Authors:  Paolo Boscolo-Rizzo; Giancarlo Tirelli; Monica Mantovani; Vittorio Baggio; Valentina Lupato; Giacomo Spinato; Alessandro Gava; Maria Cristina Da Mosto
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-11-04       Impact factor: 2.503

2.  Elevation of MiR-9-3p suppresses the epithelial-mesenchymal transition of nasopharyngeal carcinoma cells via down-regulating FN1, ITGB1 and ITGAV.

Authors:  Yu Ding; Yinghua Pan; Shan Liu; Feng Jiang; Junbo Jiao
Journal:  Cancer Biol Ther       Date:  2017-06-14       Impact factor: 4.742

3.  Late toxicity, evolving radiotherapy techniques, and quality of life in nasopharyngeal carcinoma.

Authors:  Luciana Lastrucci; Silvia Bertocci; Vittorio Bini; Simona Borghesi; Roberta De Majo; Andrea Rampini; Paola Pernici; Pietro Giovanni Gennari
Journal:  Radiol Med       Date:  2017-01-09       Impact factor: 3.469

4.  Multidimensional fatigue in patients with nasopharyngeal carcinoma receiving concurrent chemoradiotherapy: incidence, severity, and risk factors.

Authors:  Lin-Min Chen; Qiu-Lan Yang; Yu-Yu Duan; Xue-Zhen Huan; Yan He; Cong Wang; Yu-Ying Fan; Yu-Cong Cai; Jian-Mei Li; Li-Ping Chen; Hui-Ying Qin
Journal:  Support Care Cancer       Date:  2021-02-15       Impact factor: 3.603

5.  A Pairwise Meta-Analysis of Induction Chemotherapy in Nasopharyngeal Carcinoma.

Authors:  Pu-Yun OuYang; Xiao-Min Zhang; Xing-Sheng Qiu; Zhi-Qiao Liu; Lixia Lu; Yuan-Hong Gao; Fang-Yun Xie
Journal:  Oncologist       Date:  2019-02-19

6.  Comparison between nedaplatin and cisplatin plus docetaxel combined with intensity-modulated radiotherapy for locoregionally advanced nasopharyngeal carcinoma: a multicenter randomized phase II clinical trial.

Authors:  Chunyuan Tang; Fang Wu; Rensheng Wang; Heming Lu; Guisheng Li; Meilian Liu; Haisheng Zhu; Jinxian Zhu; Yong Zhang; Kai Hu
Journal:  Am J Cancer Res       Date:  2016-09-01       Impact factor: 6.166

7.  Improvement and prognosis analysis of nimotuzumab combined with TP regimen induction chemotherapy and sequential concurrent chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma.

Authors:  Weihong Luan; Haozhan Yuan; Wei Hou; Jing Li; Liping Liu
Journal:  Am J Transl Res       Date:  2022-08-15       Impact factor: 3.940

8.  Survival benefit of induction chemotherapy for locally advanced nasopharyngeal carcinoma: prognosis based on a new risk estimation model.

Authors:  Wei Liu; Bolong Yu; Yunfan Luo; Junzheng Li; Xiaofei Yuan; Shuting Wu; Bijun Liang; Zehong Lv; Yanfei Li; Xinyu Peng; Juan Lu; Xiaohong Peng; Xiong Liu
Journal:  BMC Cancer       Date:  2021-05-29       Impact factor: 4.430

9.  Outcomes of patients with nasopharyngeal carcinoma treated with intensity-modulated radiotherapy.

Authors:  Shyh-An Yeh; Tzer-Zen Hwang; Chih-Chun Wang; Chuen-Chien Yang; Ching-Feng Lien; Chien-Chung Wang; Tun-Yen Hsu; Ruey-Feng Hsu; Yu-Chen Shih; Yaw-Chang Huang; Meng-Che Hsieh; Jhy-Shyan Gau; Liyun Chang; Tsair-Fwu Lee
Journal:  J Radiat Res       Date:  2021-05-12       Impact factor: 2.724

10.  A comprehensive model based on temporal dynamics of peripheral T cell repertoire for predicting post-treatment distant metastasis of nasopharyngeal carcinoma.

Authors:  Yajing Zhang; Yujie Zhu; Jiaqi Wang; Yi Xu; Zekun Wang; Yang Liu; Xuebing Di; Lin Feng; Ye Zhang
Journal:  Cancer Immunol Immunother       Date:  2021-08-03       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.